BGLC — Bionexus Gene Lab Share Price
Last trade - 00:00- $207.17m
- $206.60m
- $13.36m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 29.06 | ||
| Price to Tang. Book | 29.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 16.01 | ||
| EV to EBITDA | 242.67 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.23% | ||
| Return on Equity | 6.18% | ||
| Operating Margin | 5.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.11 | 0.21 | 0.13 | 11.39 | 13.36 | n/a | n/a | 233.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -58.7 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioNexus Gene Lab Corp. is an emerging molecular diagnostics company. The Company is focused on the application of functional genomics to enable early diagnosis and personalized health management. The Company's wholly owned subsidiaries include Bionexus Gene Lab Sdn. Bhd. (Bionexus Malaysia) and Chemrex Sdn. Bhd. (Chemrex). BioNexus Malaysia owns algorithm software, technology and know-how related to the detection of common diseases through blood analysis which it uses in its business. Its non-invasive blood screening tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of approximately 11 different diseases. These diseases include cancers, bowel diseases and osteoarthritis. Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asia Pacific region.
Directors
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- May 12th, 2017
- Public Since
- February 21st, 2020
- No. of Shareholders
- 319
- No. of Employees
- 8
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 171,218,152
- Address
- Tower B, Vertical Business Suite, 10-2,, KUALA LUMPUR, 59200
- Web
- https://www.bionexusgenelab.com/
- Phone
- +null 160122126512
- Auditors
- JP CENTURION & PARTNERS PLT
Similar to BGLC
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
ACI Global
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
FAQ
As of Today at 13:03 UTC, shares in Bionexus Gene Lab are trading at $1.21. This share price information is delayed by 15 minutes.
Shares in Bionexus Gene Lab last closed at $1.21 and the price had moved by -36.32% over the past 365 days. In terms of relative price strength the Bionexus Gene Lab share price has underperformed the S&P500 Index by -22.3% over the past year.
There is no consensus recommendation for this security.
Bionexus Gene Lab does not currently pay a dividend.
Bionexus Gene Lab does not currently pay a dividend.
Bionexus Gene Lab does not currently pay a dividend.
To buy shares in Bionexus Gene Lab you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.21, shares in Bionexus Gene Lab had a market capitalisation of $207.17m.
Here are the trading details for Bionexus Gene Lab:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BGLC
Based on an overall assessment of its quality, value and momentum Bionexus Gene Lab is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionexus Gene Lab. Over the past six months, its share price has underperformed the S&P500 Index by -20.8%.
As of the last closing price of $1.21, shares in Bionexus Gene Lab were trading -28.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bionexus Gene Lab PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Bionexus Gene Lab's directors